India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
The Russian Ministry of Health has registered the third Russian generic of the original drug Ozempic (semaglutide) from Danish drugmaker Novo Nordisk. 8 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024
Improving the availability of innovative medicines in Latin America is a key priority for the pharmaceutical industry, policymakers, and patients. 31 March 2023
The expiration of the patent for palbociclib, a leading anti-breast cancer drug, in India has opened up new opportunities for generic versions of the drug. The Indian government highlighted this development in Parliament and intensely discussed the endless possibilities that could arise from the availability of generic palbociclib and other similar generic oncology drugs, reports The Pharma Letter’s India correspondent. 30 March 2023
Danish diabetes care giant Novo Nordisk has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of the current year. 29 March 2023
Russia will allow domestic drugmakers to develop generics of original foreign drugs under patent protection only in case of exodus of their producers from the Russian market. 29 March 2023
The niche of Western pharmaceutical companies that have suspended their clinical trials in Russia may be replaced by their competitors from the Asia Pacific as well as Middle East region, according to recent statements by some leading Russian analysts in the field of pharmaceutical business and some local media, reports The Pharma Letter’s correspondent. 22 March 2023
Research-based Egyptian pharma company Gennecs Pharmaceuticals, part of the Gennecs group, belongs to the to El Daba Holding Group, a trading conglomerate serving Egypt and the countries of the Gulf Cooperation Council that partners with local and international investors. 20 March 2023
Russia may face a shortage of rare disease drug Cuprenil (penicillamine), according to government procurement statistics data and the statistics of the commercial retail, reports The Pharma Letter’s local correspondent. 14 March 2023
Sales of Russian drugs grew in 2022 due to an increase of advertising budgets and a decline of the share of foreign drugs, reports The Pharma Letter’s local correspondent. 14 March 2023
In June 2021, the US Food and Drug Administration (FDA) approved Novo Nordisk’s (NOV: N) type 2 diabetes drug Wegovy (semaglutide) injection for chronic weight management in overweight or obese adults with at least one weight-related condition.1 This is just one example of the potential for existing drugs to offer new uses – also known as drug repurposing. 14 March 2023
March is Wilson’s Disease Awareness Month – an opportunity to raise awareness and explore progress within the management and treatment of this rare condition. 13 March 2023
Keen to accelerate vaccine drug development and approvals in India, an expert committee of India's Central Drugs Standard Control Organization (CDSCO) met recently to review the research efforts of pharmaceutical companies. 10 March 2023
Zeta Pharma is a fast-growing branded generic pharmaceutical company in the Egyptian market that was established in 2010 and started its production and marketing activities in 2015 on the hepatitis C virus products products Sofocivir, Zetaciver and Sofocivir Plus. 10 March 2023
The Russian drugmaker R-Pharm is accelerating its expansion in the domestic market this year with the planned investments of 4 billion roubles ($100 million) in the building a new production facility in St Petersburg and the establishment of a large-scale production in the capital city of Moscow. 7 March 2023
Original drugs have begun to be massively replaced by generics in the Russian pharmaceutical market, which is mainly due to falling real incomes of local customers and the overall negative situation in the country’s economy, reports The Pharma Letter’s local correspondent. 7 March 2023
Russia may be facing a shortage of erectile dysfunction drug Viagra (sildenafil) – once the best-selling medicine in the country- due to the recent announcement by the USA’s Viatris about the suspension of supplies to the drug to the Russian market. 28 February 2023
Even as the US Food and Drug Administration’s (FDA) director of drug quality Carmelo Rosa recently emphasized the need for Indian pharmaceutical companies to continually strive to manufacture drugs of the highest quality, both domestically and internationally, the Indian government has gone into overdrive to ensure that the impeccable standards of its regulatory mechanisms can be maintained over the long-term, reports The Pharma Letter’s India correspondent. 27 February 2023
Rare Disease Day is honored globally on February 28 each year. For a long time, the number of known rare diseases in the world was pegged between 6,000 and 8,000. 23 February 2023
The range medicines available in Russian pharmacies is steadily declining, which is mainly due to tough economic environment in the country, caused by Western sanctions and the existing problems with logistics, reports The Pharma Letter’s local correspondent. 14 February 2023
The advent of biologics has opened doors for the treatment of several acute and chronic medical conditions.1 Unlike conventional medicines, biologics are derived from living organisms using complex biomedical processes. As a result, development of biologics is more complicated as compared to conventional drugs.2 14 February 2023
The courts in India have come down heavily against certain domestic pharmaceutical companies who have been accused of allegedly flagrantly violating patent policies, with many launching drugs that are still covered by patents, reports The Pharma Letter’s India correspondent. 11 February 2023